The effectiveness of combined therapy in patients with acne and undifferentiated connective tissue dysplasia

Close metadata

RELEVANCE

Of the topic is the need to develop the effective methods of acne treatment in patients with connective tissue dysplasia.

OBJECTIVE

Evaluation of acne treatment effectiveness in patients with undifferentiated connective tissue dysplasia (UCTD) using combination of 1% clindamycin phosphate and 15% azelaic acid.

MATERIAL AND METHODS

The study included 61 patients (mean age 25.4±5.1 years) with mild to moderate acne and signs of UCTD. Depending on the number of revealed signs of UCTD, patients were divided into 2 groups: main group (n=27) and comparison group (n=34). The severity of acne was assessed using the dermatological index of acne (DIA) after 4, 6 and 8 weeks of drugs’ application. All patients were prescribed the combined topical therapy with 1% clindamycin phosphate — «Klindavit» gel (morning) and 15% azelaic acid — «Azelik» gel (evening). The effectiveness of treatment was assessed by such criteria as clinical recovery, clinical improvement, and lack of effect.

RESULTS

In patients of the main group, signs of dysplasia of the cardiovascular system, gastrointestinal tract, osteo-articular and asthenic syndromes prevailed, in the comparison group — asthenic syndrome, gastroenterological phenes, signs of dysplasia of the eyes, thrombocytopathy. As a result of 8 weeks combined therapy, clinical improvement was achieved in both groups. In the main group, DIA decreased from 9.43±0.67 to 6.58±0.57 points (p<0.05), in the comparison group — from 7.04±0.56 to 4.86±0.60 points (p<0.05).

CONCLUSION

External (topical) combined therapy of patients with acne and UCTD using 1% clindamycin phosphate and 15% azelaic acid made it possible to achieve a good clinical effect in both patients’ groups, however, in the main group the less positive DIA dynamics was observed than in group of comparison.

Keywords:

acne

undifferentiated connective tissue dysplasia

clindamycin

azelaic acid

Authors:

Matushevskaya E.V.

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA

ORCID: 0000-0003-4583-0617

Zagrtdinova R.N.

Izhevsk State Medical Academy

Matushevskaya Yu.I.

Lyubertsy skin and Venereological dispensary

Received:

20.07.2020

Accepted:

06.09.2020

List of references:

Kubanova AA, Kubanov AA, Samcov AV, Aravijskaya ER. Akne. Federal’nye klinicheskie rekomendacii. Dermatovenerologiya: Bolezni kozhi. Infekcii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoj ehkspress; 2016. (In Russ.).
Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolescent Health Med Ther. 2016;(7):13-25. https://doi.org/10.2147/AHMT.S55832
Nast A, Dreno B, Bettoli V. European Evidence-based (S3) Guidelines for the Treatment of Acne. JEADV. 2012;26(1):1-29. https://doi.org/10.1111/j.1468-3083.2011.04374.x
Samcov AV. Topical antibiotics in the treatment of acne. Vestnik dermatologii i venerologii. 2011;1:84-85. (In Russ.).
Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(6):9-25.
Silina LV, Pis’mennaya EV, Kolbina MS. Topical antibiotics in acne therapy. Vestnik dermatologii i venerologii. 2016;2:115-120. (In Russ.).
Alirezaï M, Gerlach B, Horvath A & Forsea D. Clindamycin gel, 1% once a day versus clindamycin solution, 1% twice a day and clindamycin gel vehicle in the treatment of acne vulgaris. Journal of the American Academy of Dermatology. 2004;50(3):13. https://doi.org/10.1016/j.jaad.2003.10.057
Ditre, Kristen Whitney K, Anti-Inflammatory Properties of Clindamycin: A Review of Its Use in the Treatment of Acne Vulgaris. Clinical Medicine Insights: Dermatology. 2011;8:27. https://doi.org/10.4137/cmd.s5058
Shahlita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison. Arch Dermatol. 1984; 120(3):351-355. https://doi.org/10.1001/archderm.120.3.351
Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol. 1987;116(3):387-391. https://doi.org/10.1111/j.1365-2133.1987.tb05853.x
Webster GF. Acne vulgaris* Commentary: A UK primary care perspective on treating acne. BMJ. 2002;325(7362):475-479. https://doi.org/10.1136/bmj.325.7362.475
Gorjachkina MV, Belousova TA, Vladimirov VV, Vertieva EJu. Clinical experience of using 1% clindamycin gel for papulo-pustular acne. Dermatologija. Prilozhenie k zhurnalu Consilium Medicum. 2014;4:10-14. (In Russ.).
Potekaev NN. Clindamycin of external antibiotic therapy for acne vulgaris. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2011;2(9):70-72. (In Russ.).
Dombrovskaya DK, Monachov KN. Expediency of combination of external antibacterial therapy and azelaic acid preparations in the treatment of acne patients. Vestnik dermatologii i venerologii. 2016;(5):79-83. (In Russ.).
Pazoki-Toroudi H, Nilforoushzadeh MA, Ajami M, Jaffary F, Aboutaleb N, Nassiri-Kashani M &Firooz A. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology. 2011;30(4):286-291. https://doi.org/10.3109/15569527.2011.581257
Thiboutot D. New Treatments and Therapeutic Strategies for Acne. Archives of Family Medicin. 2000;9(2):179-187. https://doi.org/10.1001/archfami.9.2.179
Kainz JT, Berghammer G, Auer-Grumbach P, Lackner V, Perl-Convalexius S, Popa R, et al. Azelaic acid 20% cream: effects on quality of life and disease severity in adult female acne patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2016;14(12):1249-1259. https://doi.org/10.1111/ddg.12889
Kondratyeva YS, Kokina OA. Experience of applying azelaic acid in dermatology. Vestnik dermatologii i venerologii. 2016;3:139-144. (In Russ.).
Gollnick HP, Graupe K, Zaumseil R-P. Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft. 2004; 2(10):841-847. https://doi.org/10.1046/j.1439-0353.2004.04731.x
Monakhov KN, Dombrovskaya DK. Kompleksnaya naruzhnaya terapiya vul’garnykh ugrei. Vestnik dermatologii i venerologii. 2012;3:104-106. (In Russ.).
Schaller M, Sebastian M, Ress C, Hennig M. A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3% clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. JEADV. 2016;30(6):966-973. https://doi.org/10.1111/jdv.13541
Guidelines of the Russian scientific medical society of internal medicine on the diagnosis, treatment and rehabilitation of patients with the connective tissue dysplasia (first edition). Meditsinskii Vestnik Severnogo Kavkaza. 2018; 1.2:137-209. (In Russ.). https://doi.org/10.14300/mnnc.2018.13037
Kadurina TI, Gorbunova VN. Connective tissue dysplasia. SPb.: Elbi; 2009. (In Russ.).
Chiu C-H. Effect of a C/EBP gene replacement on mitochondrial biogenesis in fat cells. Genes & Development. Cold Spring Harbor Laboratory. 2004;18(16):1970-1975. https://doi.org/10.1101/gad.1213104
Koshel MV. Difficult course of acne and connective tissue dysplasia. Nuchnoe obozrenie. Medicinskie nauki. 2014;1:159-159. Accessed Mar 1, 2020 (In Russ.). https://science-medicine.ru/ru/article/view?id=238
Nechaeva GI, YAkovlev VM, Konev VP. Connective tissue dysplasia: the main clinical syndromes, formulation of diagnosis, treatment. Lechaschii vrach. 2008;2:22-28. (In Russ.).
Kochergin NA, Samgin MA, Monakhov SA, Ignat’ev D. Dermatologic index acne. Esteticheskaya meditsina. 2004;3(1):62-65. (In Russ.).
Rebrova OYu. Statistical analysis of medical information. Application of software package Statistica. M.: MediaSfera; 2002. (In Russ.).

Close metadata